US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Lennar Corp (0JU0) 銘柄情報

Lennar Corp (0JU0)

52.27

0.00

(0.00%)

終了 7月5日 12:30AM

Lennar Corp (0JU0) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

52.27

( - )

買値

52.27

売値

52.27

出来高

0.00

0.00 日の範囲 0.00

52.27 52 週間の範囲 52.27

時価総額

前日終値

52.27

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 2,790,392

発行済株式数

240,895,142

配当利回り

2 (2.21%)

PER

13.53

1 株当たり利益 (EPS)

6.43

歳入

32.74B

純利益

1.62B

Lennar Corporation, together with its subsidiaries, operates as a homebuilder primarily under the Lennar brand in the United States. It operates through Homebuilding East, Homebuilding Central, Homebuilding South Central, Homebuilding West, Financial Services, Multifamily, and Lennar Other segments.... Lennar Corporation, together with its subsidiaries, operates as a homebuilder primarily under the Lennar brand in the United States. It operates through Homebuilding East, Homebuilding Central, Homebuilding South Central, Homebuilding West, Financial Services, Multifamily, and Lennar Other segments. The company’s homebuilding operations include the construction and sale of single-family attached and detached homes, as well as the purchase, development, and sale of residential land; and development, construction, and management of multifamily rental properties. It also offers residential mortgage financing, title insurance, and closing services for home buyers and others, as well as originating and selling securitization commercial mortgage loans. In addition, the company is involved in fund investment activities. It primarily serves first-time, move-up, active adult, and luxury homebuyers. The company was founded in 1954 and is based in Miami, Florida. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.lennar.com

本社

Miami, United States

設立

2026

Lennar Corp is listed in the sector of the ロンドン証券取引所 with ticker 0JU0. The last closing price for Lennar was US$52.27. Over the last year, Lennar shares have traded in a share price range of US$ 52.27 to US$ 52.27.

Lennar currently has 240,895,142 shares in issue. The market capitalisation of Lennar is US$12.59 billion. Lennar has a price to earnings ratio (PE ratio) of 13.53.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	52.27	52.27	52.27	1687	52.27	DE
52	0	0	52.27	52.27	52.27	1801	52.27	DE
156	0	0	52.27	52.27	52.27	1904	52.27	DE
260	0	0	52.27	52.27	52.27	2190	52.27	DE

0JU0 - Frequently Asked Questions (FAQ)

What is the current Lennar Corp share price?

The current share price of Lennar Corp is US$ 52.27

How many Lennar Corp shares are in issue?

Lennar Corp has 240,895,142 shares in issue

What is the market cap of Lennar Corp?

The market capitalisation of Lennar Corp is USD 12.59B

What is the 1 year trading range for Lennar Corp share price?

Lennar Corp has traded in the range of US$ 52.27 to US$ 52.27 during the past year

What is the PE ratio of Lennar Corp?

The price to earnings ratio of Lennar Corp is 13.53

What is the cash to sales ratio of Lennar Corp?

The cash to sales ratio of Lennar Corp is 0.64

What is the registered address of Lennar Corp?

The registered address for Lennar Corp is 5505 Waterford District Drive, Miami, Florida, 33126

What is the Lennar Corp website address?

The website address for Lennar Corp is www.lennar.com

weenphan

weenphan 9分前

https://www.otcmarkets.com/stock/CVALF/profile

Kool Aid Man

Kool Aid Man 10分前

Measly $44k left in the gas tank

40 million shares left to issue x .0011

No one goes public if they intend to self finance operations. The whole point is to print and sell shares to raise money...not to reward old bag holders who were conned by Miro years ago. Why split

jondoeuk

jondoeuk 11分前

Calling this the "gold standard" doesn't answer all the underlying concerns. This isn't a refinement of the original external-control analysis either. It uses a completely different set of external comparator trials. That means the reported survival estimate depends on which external patients are se

manibiotech

manibiotech 13分前

Yes we all know that . The previous external control arm patients were “external” , and the one’s in new PSM analysis are also different ‘external’ patients with patient level propensity matching ( so even better controls) and show even better treatment benefit . So again, what is the point you are

Naught

Naught 13分前

Should we expect some notices from. PAC in the very near term then...?

weenphan

weenphan 14分前

I posted on the PCHM board for over a decade. I bought PCHM as low as .0013 and sold stock as high as $5 plus. It was a once in a lifetime percentage gainer. My aliases were LMLYP, Rosesarefree and GeneandDean, which all are references to a band Ween. I'm weenphan on this board.

newflow

newflow 14分前

Ron, Dissolved vs Extinct
No Altaba distributed immediately before dissolution, can you find any company distributing value to equity holders after its complete dissolution long-form or regular Dissolution.
Gemini's Response:
It is important to clarify a key point about Delaware

DA88

Can someone explain who this guy is and why his perspective matters? Love that he is positive, but he doesn’t look like he is anything more than a shareholder.

PickStocks

PickStocks 17分前

Yes….but we do not have anything to do with Paladin. So it means nothing which is easily verified by a simple phone call….

jondoeuk

jondoeuk 21分前

Whether this particular analysis has been submitted is something nobody outside NWBO and the MHRA knows.

jondoeuk

jondoeuk 23分前

This is not simply a refinement of the published JAMA Oncology analysis. It's a different external-control analysis built from a different pool of comparator trials. The fact they constructed a propensity-score matched analysis using individual patient data from AVAGLIO, CENTRIC, and CORE, means the

ihorchu

ihorchu 25分前

A fantastic day to remember! Since no humidity here, heat is very tolerable.

jondoeuk

jondoeuk 31分前

'While encouraging, our clinical findings must be interpreted with caution. Even though this was a randomized clinical trial (randomization software assigned patients to TLR agonist/placebo groups), the small number of patients enrolled contributed to an imbalance in patient selection between the tr

kevindenver

kevindenver 31分前

Nowhere in the interview was "Blarcamesine" mentioned. There was a snippet towards the end where autophagy is mentioned.

Maybe you hallucinated that this interview was related to blarcamesine?

A transcript of the interview can be found here:
https://podcasts.hap

TightCoil

TightCoil 39分前

Yes, next week is the week we FLY

TightCoil

TightCoil 41分前

FNMA/FMCC
On Schwab Now
FNMA ask $7.33
FMCC ask $9.31
Load up Early
Remember:Again- Will you be quick enough to grab some of these shares once one or more current "announcements in the making," are made? Will you be quicker than the big gun buying stampede when eve

JonDoe1

JonDoe1 42分前

He's extra angry today. Possibly hit the 4th of July drinks a little early. That poor keyboard.

kenjiroo

kenjiroo 42分前

Happy 4th longs !!!

US Market News

US Market News 43分前

SK Telecom Pursues 15GW AI Data Center Buildout, Aiming to Become Asia's AI Infrastructure HubJuly 4, 2026 8:29 PM
PR Newswire (US) Ulsan AI Data Center to expand to GW scale; 5GW to be activated in stages from 2029, reaching 15GW in to

long_haul

long_haul 43分前

I like this guy a lot ! Next week is going to be fire

JonDoe1

JonDoe1 43分前

STOP RESPONDING TO MY POSTS

It's a public forum.

garyhalvo

garyhalvo 46分前

IMO, September 13th will probably end because I believe that all of those dates that were posted with the court has come and went, so I don’t see anything in the way. How long will it be till we get our money after that, I think by the end of September.

CHILLWILL1704

CHILLWILL1704 46分前

wheres the restaurant--I wanna go say hi-any body else want to go?

imafan

imafan 49分前

Shorts and Eric haters, you'll know who they are when they respond, have got to be extremely disappointed Eric is succeeding! They'll be more HUUUUGE confirmed announcements coming SHORTly! Sooo Entertaining!!! ONWARD!!!

CAD vs Sterling

Inmolecule Nanotech

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。